Modella AI
Category: AI in Healthcare
A generative AI company developing multimodal foundation models for pathology and oncology to accelerate drug discovery and precision medicine. Modella AI was founded in 2022. The company is led by Jill Stefanelli. Based in Boston, USA. Team size: 10-50. Total funding raised: Undisclosed. Latest round: Acquisition (Jan 2026). Key investors include AstraZeneca, Mass General Brigham.
- Founded
- 2022
- Headquarters
- Boston, USA
- Team size
- 10-50
- Total funding
- Undisclosed
Value proposition
Accelerates oncology R&D by transforming complex pathology data into actionable insights through generative AI, reducing drug development timelines and improving diagnostic accuracy.
Products and solutions
PathChat (Multimodal generative AI copilot for pathology), PathChat DX (Diagnostic tool with FDA Breakthrough Device Designation), Multimodal Foundation Models for Oncology, Computational Pathology Analytics Platform
Unique value
Pioneered 'PathChat,' a first-of-its-kind vision-language foundation model for pathology that allows users to interact with tissue images using natural language, published in Nature.
Target customer
Biopharmaceutical companies, oncology R&D departments, clinical researchers, and diagnostic laboratories.
Industries served
Biotechnology, Pharmaceuticals, Healthcare AI, Oncology
Technology advantage
Leverages proprietary multimodal AI that integrates histopathology images with clinical text, providing a deeper biological understanding than traditional unimodal computer vision tools.
How they differentiate
Pioneered 'PathChat,' a vision-language foundation model (VLM) for pathology that enables natural language interaction with tissue images, providing deeper biological context than traditional computer vision tools.
Main competitors
Paige AI, PathAI, Owkin
Key partnerships
AstraZeneca (Strategic Acquirer), Mass General Brigham (Licensing and Research Partner), Harvard Medical School (Academic Collaboration)
Notable customers
AstraZeneca, Mass General Brigham
Major milestones
Publication of PathChat (multimodal generative AI copilot) in Nature (2024), Secured FDA Breakthrough Device Designation for PathChat DX (Jan 2025), Acquired by AstraZeneca to accelerate oncology drug discovery and clinical development (Jan 2026)
Growth metrics
Transitioned from academic spin-off to strategic acquisition in under 3 years; secured FDA Breakthrough Device Designation for PathChat DX.
Market positioning
Strategic AI-driven oncology R&D accelerator, now integrated into AstraZeneca's global precision medicine pipeline.
Geographic focus
North America (HQ in Boston), Global (via AstraZeneca's R&D footprint)
Patents and IP
Holds exclusive licenses for computational pathology technology from Mass General Brigham; proprietary generative AI architectures.
About Jill Stefanelli
Jill Stefanelli is a seasoned executive with over 20 years of experience in precision medicine and diagnostics. Prior to co-founding Modella AI, she served as President and Chief Business Officer at Paige AI, a leader in computational pathology. Her career includes senior leadership roles such as Senior Vice President of Partnerships at Invitae (following its acquisition of ArcherDX) and key positions at Thermo Fisher Scientific and Roche Diagnostics, where she focused on global companion diagnostic alliances and oncology strategy.
Official website: https://www.modella.ai